NEW YORK, Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Marrone Bio Innovations, Inc. (“Marrone Bio” or the “Company”) (NASDAQ: MBII) in connection with the proposed merger of the Company with Bioceres Solutions Corp. (“Bioceres”) (NASDAQ: BIOX).
Under the terms of the merger agreement, each share of MBI common stock owned will be exchanged at closing for ordinary shares of Bioceres at a fixed ratio of 0.088, representing implied per-share merger consideration of approximately $1.18 based upon Bioceres’s March 17, 2022 closing price of $13.35.
Weiss Law is investigating whether: (i) Marrone Bio’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Marrone Bio’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.
Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices).
This article was shared with Prittle Prattle News as a Press Release by PRNewswire.
